On Wednesday, Shares of Transocean LTD (NYSE:RIG), lost -5.73% to $13.66.
Transocean issued a monthly Fleet Update Summary, which comprises new contracts, changes to existing contracts, and changes in estimated planned out-of-service time of 15 or more days since the August 19, 2015 Fleet Update Summary.
The report comprises the following:
- The Transocean Barents, GSF Rig 140, and GSF Galaxy II are idle.
- Estimated 2015 out-of-service time raised by a net 26 days; 2016 reduced by a net five days.
Transocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. The Company’s primary business is to contract its drilling rigs, related equipment and work crews primarily on a day rate basis to drill oil and gas wells.
Shares of Heron Therapeutics Inc (NASDAQ:HRTX), inclined 21.60% to $40.81, during its last trading session.
Heron Therapeutics declared positive, top-line results from its Phase 2 clinical study of HTX-011 in the administration of post-operative pain in patients undergoing bunionectomy. HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. The primary and all key secondary endpoints in the study were met with a high degree of statistical significance.
This randomized, placebo-controlled, double-blind, Phase 2 clinical study in 64 patients undergoing bunionectomy evaluated the efficacy and safety of HTX-011, containing 200 mg or 400 mg of bupivacaine combined with meloxicam, contrast to placebo. The primary endpoint was the difference as contrast to placebo in pain intensity as measured by the Summed Pain Intensity (SPI) score in the first 24 hours post-surgery (SPI 0-24). Key secondary endpoints comprised: the difference in SPI in the first 48 hours post-surgery (SPI 0-48); the difference in SPI in the first 72 hours post-surgery (SPI 0-72); time to the first use of opiate rescue medication; and the percent of patients who received no opiate rescue medication in the first 72 hours post-surgery.
Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company’s product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials.
Shares of Annaly Capital Management, Inc. (NYSE:NLY), inclined 1.06% to $10.51, during its last trading session.
The Board of Directors of Annaly Capital Management declared the third quarter 2015 common stock cash dividend of $0.30 per common share. This dividend is payable October 30, 2015, to common shareholders of record on September 30, 2015. The ex-dividend date is September 28, 2015.
Dividends may be reinvested through the Company’s Dividend Reinvestment and Share Purchase Plan. Plan information may be obtained from the Plan Administrator, Computershare at 1-800-301-5234, at www.annaly.com, or by contacting the Company.
Annaly’s principal business objective is to generate net income for distribution to its shareholders from its investments. Annaly is a Maryland corporation that has elected to be taxed as a real estate investment trust (“REIT”). Annaly is managed and advised by Annaly Administration Company LLC.
Annaly Capital Management, Inc. is a mortgage real estate investment trust (REIT). The Company uses its capital coupled with borrowed funds to invest in real estate related investments, earning the spread between the yield on its assets and the cost of its borrowings.
Finally, Delta Air Lines, Inc. (NYSE:DAL), ended its last trade with 0.28% gain, and closed at $46.59.
Newly integrated with UATP, Givex is now able to provide its platform, counting gift cards, to airlines across the world. Givex has just signed major carrier Delta Air Lines to use this platform. The partnership between UATP and Givex expands airlines’ offerings to meet customer demand for additional payment options.
Gift cards, already a $124 billion per year industry, are the preferred gift for recently’s consumers. Now airlines will have the capability to redeem gift cards for goods sold onboard the plane, in airport terminals, ancillaries or towards airline tickets themselves.
UATP is the low cost payment network privately owned by the world’s airlines. Givex is the expert in gift cards and stored value tickets (in addition to loyalty and POS). Together Givex and UATP can provide airlines with innovations such as gift cards towards airline tickets and ancillaries.
Delta Air Lines, Inc. (Delta) provides scheduled air transportation for passengers and cargo throughout the United States and around the world. The Company’s route network is centered on a system of hub and international gateway airports that it operates in Amsterdam, Atlanta, Detroit, Los Angeles, Minneapolis-St.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
